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Summary
Rare inherited bleeding disorders (IBD) are a common cause of bleeding
tendency. To ensure a correct diagnosis, specialized laboratory analyses are
necessary. This study reports the results of an upfront diagnostic strategy
using targeted whole exome sequencing. In total, 156 patients with a signif-
icant bleeding assessment tool score participated in the study, of which a
third had thrombocytopenia. Eighty-seven genes specifically associated with
genetic predisposition to bleeding were analysed by whole exome sequenc-
ing. Variants were classified according to the five-tier scheme. We identified
353 germline variants. Eight patients (5%) harboured a known pathogenic
variant. Of the 345 previously unknown variants, computational analyses
predicted 99 to be significant. Further filtration according to the Mendelian
inheritance pattern, resulted in 59 variants being predicted to be clinically
significant. Moreover, 34% (20/59) were assigned as novel class 4 or 5 vari-
ants upon targeted functional testing. A class 4 or 5 variant was identified
in 30% of patients with thrombocytopenia (14/47) versus 11% of patients
with a normal platelet count (12/109) (P < 001). An IBD diagnosis has a
major clinical impact. The genetic investigations detailed here extricated
our patients from a diagnostic conundrum, thus demonstrating that con-
tinuous optimization of the diagnostic work-up of IBD is of great benefit.
Keywords: bleeding disorders, genetic analysis, platelet disorders.
Rare inherited bleeding disorders (IBD) are a heterogeneous
group of diseases that are very complex to diagnose. The
work-up of patients with mild bleeding disorders is ham-
pered by the fact that the number of possible causes is exten-
sive (>51 different inherited platelet abnormalities have been
genetically described) but the incidence of each defect is very
low (<1/100 000) (Nurden & Nurden, 2013; Lentaigne et al,
2016). Some patients may have several defects working in
concert to produce a mild bleeding disorder (Stockley et al,
2015). Bleeding tendency may also be caused by vascular
defects, such as Ehlers–Danlos syndrome (EDS) or hereditary
telangiectasia (HT). Thus, a correct diagnosis requires not
only a careful interview on symptoms and family history but
also functional and, in many cases, genetic testing. Advanced
functional platelet assays are only available at specialized
coagulation centres and do not cover vascular or connective
tissue disorders. In the pre-molecular genetics era, the mere
complexity (and cost) of these investigations rendered a sig-
nificant proportion of patients, between 47–67%, without a
proper diagnosis (Quiroga & Mezzano, 2012).
Advances in gene sequencing techniques, enforced by the
Human Genome Project, have made the rapid sequencing of
multiple genes a promising tool in the diagnostic work-up of
these patients. A remarkable effort has been made by the
ThromboGenomics consortium that has designed an next
generation sequencing (NGS)-based panel targeting 63 genes
relevant for inherited bleeding and thrombotic disorders,
allowing for a molecular diagnosis in cases where an IBD or
thrombotic disorder is suspected on laboratory or clinical
findings (Simeoni et al, 2016). Another approach has been
taken by the UK Genotyping and Phenotyping of Platelets
(GAPP) study that enrols patients with increased bleeding
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tendency of unknown aetiology. In this study, the presence
of known genetic causes is ruled out by functional and
genetic testing. The GAPP study recently showed that a pla-
telet defect was identified in approximately 60% of the inves-
tigated participants (>500 patients) by using whole exome
sequencing (WES) techniques (Fletcher et al, 2015; Watson
et al, 2013).
The advantage of WES compared to gene panels is the
option to consecutively expand the number of genes analysed
as information on the underlying genetic disorders increases.
As for all new screening methods, caution must be taken
when interpreting the results, especially in regard to variant
filtering. Hence, WES identifies tens of thousands of variants
in each patient, of which the majority are common benign
variants that are filtered out by bioinformatics tools. How-
ever, a large number of variants need interpretation and sub-
sequent classification. Classification of the clinical
significance of a genetic variant ranges from benign to patho-
genic and, to ensure a consistent and standardized output,
variant classification must follow international consensus-
based guidelines (Amendola et al, 2016; Rehm et al, 2013;
Richards et al, 2015; Matthijs et al, 2016).
In the present study, to improve the diagnostic outcome
in patients referred for an IBD, we applied WES to identify
variants in 87 preselected, already known disease-associated
genes. Variants were classified according to the five-tier
scheme. Variants of unknown significance (VUS) were fur-
ther filtered according to their Mendelian inheritance pat-
terns as well as in silico analyses. Prior to initiation of the
WES strategy, only patients with an established diagnosis of
haemophillia or Von Willebrand syndrome type 2 or sus-
pected carriers had been offered classic genetic testing at our
institutions. Ultimately, targeted functional tests were per-
formed, allowing patients suffering from excessive bleeding
to be diagnosed with IBD. The results obtained by imple-
mentation of WES at an early stage of the diagnostic work-
up in patients suspected of an IBD are presented here.
Materials and methods
Enrolment of patients
We performed the International Society on Thrombosis and
Haemostasis (ISTH) bleeding assessment tool (BAT) score
(Elbatarny et al, 2014) in all patients referred to the Depart-
ment of Haematology, Rigshospitalet (RH), Copenhagen
University Hospital, Denmark, and the Coagulation Unit,
Skaane University Hospital, Malm€o, Sweden, between April
2013 and January 2016 on the basis of a suspected IBD.
Patients without evidence of a coagulation factor deficiency
[i.e. normal levels of activated partial thromboplastin time
(APTT), International normalised ratio, prothrombin time,
fibrinogen, FVIII, von Willebrand factor antigen (VWF:Ag)
and VWF activity measured with ristocetin cofactor activity
or the glycoprotein (GP) Ib enzyme-linked immunosorbent
assay] and a significant BAT score (>3 in men, >5 in women,
>2 in children), as well as patients suspected of an inherited
thrombocytopenia, were included in the study. Prior to WES
analysis, all patients from RH received oral and written
information about WES and also the possible occurrence of
incidental findings. All patients signed informed consent to
publication of their data in concordance with the Helsinki
Declaration, and permission for data publication was granted
by the local ethics committee (H-15006580) and the data
registry (30-1470). Patients from Malm€o fulfilling the same
inclusion- and exclusion criteria were included in the study
approved by the local ethics committee (Dnr 2014/209).
After oral and written informed consent and in concordance
with the Helsinki Declaration, further blood samples were
obtained for genetic sequencing. The diagnostic flow is illus-
trated in Fig 1.
Clinical evaluation
A family history including information on relatives with
increased bleeding tendency or thrombocytopenia and con-
sanguinity was obtained for all patients. Patient ethnicity was
registered. A physical examination was performed, focussing
on skin bruising, petechiae, skin elasticity and telangiectasia.
In patients suspected of a collagen disorder, the Beighton
joint hypermobility score was performed (Zeitoun et al,
2013). In patients with symptoms of HT, the oral cavity was
thoroughly examined.
Selection of predisposing genes
Based on a continuous literature search between 2013 and
2016, 87 genes predisposing to bleeding disorders were
selected, 63 of which were platelet related and 24 were non-
platelet related (Table I and Table S1). The non-platelet
related genes included coagulation factors, ADAMTS13, plas-
minogen activator inhibitor and alpha1-antiplasmin. We also
examined EDS and HT predisposing genes. As protein disul-
phide isomerase (PDI) was recently described to play a key
role in clot formation (Jasuja et al, 2010), the P4HB gene
was included to examine whether loss-of-function in P4HB
could be a previously undiscovered cause of bleeding ten-
dency. Finally, the search was expanded to genes associated
with specific phenotypic (bleeding, thrombocytopenia,
thrombocytopathy or symptomatic (hypermobility) search
terms.
Whole exome sequencing
The exon coverage of all 87 genes was evaluated from in-
house validation exome sequencing data with a minimum
coverage of 50 9 to ensure sufficient coverage of targeted
genes. Genomic DNA was purified from whole blood using a
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. For enrichment of the
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exome either SeqCap EZ Exome v3 (Roche Nimblegen,
Madison, WI, USA) or SureSelect All Exon Kit v4 or v5
(Agilent Technologies, Santa Clara, CA, USA) was used.
Sequencing was conducted using the HiSeq2500 and Next-
Seq500 platforms from Illumina (San Diego, CA, USA). In
brief, 1 lg of genomic DNA was fragmented on a Covaris S2
(Woburn, MA, USA) to an average size of 250 bp. Up until
September 2015, the trimming, 3’-adenylation and ligation of
Illumina adaptors were performed on an SPRI-TE nucleic
acid extractor using SPRIworks Fragment Library Cartridges
I (Beckman Coulter, Brea, CA, USA) with a size selection of
200–400 bp. From September 2015, the trimming, 3’-adeny-
lation and adaptor ligations were done on a Sciclone G3
robot (Perkin Elmer, Waltham, MA, USA) using Illumina-
compatible KAPA library DNA adaptors (Roche Diagnostics,
Basel, Switzerland). Sequencing was performed as paired-end
sequencing, 2 9 101 bases or 2 9 151 bp, resulting in
approximately 100 mol/l paired-end reads. Sequencing data
were processed using Consensus Assessment of. Sequence
And Variation (CASAVA) v1.8.2 (Illumina, San Diego, CA,
USA).
Data processing
Generated fastq files were uploaded to CLC bio (Genomics
Workbench v2.5.1; Qiagen) for trimming of the last 3’ base,
mapping and variant calling. All the algorithms applied to
the samples were custom made by CLC bio. The reads were
mapped to the reference human genome hg19/GRCh37 with
custom algorithm CLC4 (https://www.qiagenbioinformatics.c
om/products/clc-genomics-workbench/) for a comparison
between the CLC4 algorithm and the most commonly known
aligners. Quality control of the target sequencing was
performed on the read mappings. The variant calling was
performed by a Maximum Likelihood approach on a Baye-
sian model. Variants were called with a minimum of 9 9
coverage, 3 counts and 25% frequency. Variants were further
filtered using the Ingenuity Variant Analysis tool (Qiagen),
excluding the low quality scores and variants (>1% in back-
ground population), and including variants found within the
87-gene list and variants associated with bleeding, thrombo-
cytopenia and thrombocytopathy as well as specific symp-
tomatic associations.
Variant classification and in silico analysis
The initial classification of identified variants was performed
according to the five-tier scheme as recommended by The
American College of Medical Genetics and Genomics
(Richards et al, 2015): class 5 is pathogenic; class 4 probably
pathogenic; class 3 uncertain significance; class 2 probably
benign; and class 1 benign. To select VUS for specific func-
tional testing, we developed the €Oresund clinical score, which
combines the Mendelian inheritance pattern with the results
of four computational analyses (Table II). We filtered out
heterozygous variants in genes known to have a recessive
Mendelian inheritance pattern. For further filtering, all the
class 3 variants were subjected to computational predictive
analyses. Given that the algorithms for missense variants are
not entirely identical and guidelines recommend a combina-
tion of the in silico tools (Richards et al, 2015), we applied
four different predictive tools: Align GVGD (A-GVGD);
PolyPhen-2; MutationTaster; and SIFT (Tavtigian et al, 2006;
Adzhubei et al, 2010; Kumar et al, 2009; Schwarz et al,
2010). If a VUS scored as ‘damaging’ in three of the four
predictive tools, we considered the computational analysis as
Clinical parameter
Paents 156
Age 39   15
Bat score 8·9   6
Females 131 (84%)
Family history 111 (71%)
Thrombocytopenia 47 (30%)
+-
+-
European (90%) 
(Non-finnish)
European (1·5%) 
(Finnish)
Latino (1·5%)
South Asian (0·5%)
East Asian (0·5%)
Other (6%)(A) (B)
Fig 1. Patient characteristics. A) Clinical parameter. BAT (bleeding assessment tool). B) Patient ethnicity
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significant and thus viewed the VUS as a possible candidate
variant for downstream functional testing. The frequency of
the variants was obtained from the Exome Aggregation Con-
sortium (ExAC, http://exac.broadinstitute.org/) or the Exome
Sequencing Project (ESP, https://embedthis.com/esp/doc/use
rs/database.html) databases. Candidate variants with an €Ore-
sund clinical score >2, selected as described above, were
examined by available specific functional tests [such as flow
cytometry (FC), transmission electron microscopy (TEM),
immunohistochemistry and plasma-thromboxane B2]. Vari-
ants of unknown significance with €Oresund score 1-2 were
left as class 3.
Initial functional testing
A peripheral blood smear was performed in all patients with
thrombocytopenia. These smears were evaluated by the Cella-
VisionTM software (CellaVision-DM1200; Sysmex, Kobe,
Japan). Giant platelets were defined as abnormal platelets
when the size of erythrocytes or larger. Macrothrombocytes
were defined as abnormal platelets when the size was between
66% and 100% that of erythrocytes. Multiplate analyses were
performed on whole blood following stimulation by four dif-
ferent agonists on a multiplate analyser (Verum Diagnostica
GmbH, Munich, Germany) (Michelson, 2009; Albanyan et al,
2015). Light transmission aggregometry (LTA) was per-
formed according to routine clinical protocols (Cattaneo
et al, 2013; Pai et al, 2011). Subjects with a platelet count
<100 9 109/l were excluded from the LTA and multiplate
analyses.
Specific functional testing
Assessment of platelet activation by FC was performed as
previously described (Nishibori et al, 1993; Stenberg et al,
1985; Shattil et al, 1985). Briefly, platelet activation and gran-
ule release were investigated by FC using markers for CD63,
CD62P and activated GPIIb/IIIa. For each patient, aliquots
of whole blood (20 ll) were incubated with 20 ll of CD42b-
APC antibodies (Cat. No. 551061; Becton Dickinson [BD],
Stockholm, Sweden) for 15 min at room temperature. Subse-
quently, 40 ll of diluted blood was incubated with 40 ll of
platelet-activating agonists and a 20-ll mix of markers for
degranulation and activation. The following agonists and
concentrations were used: ADP (Cat. No. 58-64-01; Sigma-
Aldrich, Stockholm, Sweden) final concentration (CF)
10 lmol/l and 1 lmol/l; CRP-XL (from Dr. Richard W.
Farndale, University of Cambridge, UK) CF 20 lg/ml and
2 lg/ml; collagen (CHRONO-PAR Cat. No. N-385) 1 mg/ml
and TRAP-6 (Cat. No. N-8365; Bachem, Bubendorf, Switzer-
land) CF 25 lmol/l and 5 lmol/l. The following activation
markers were used: 5 ll PAC-1-FITC (Cat. No. 340507; BD);
5 ll CD62P-PE (Cat. No. IM1759u; Beckman Coulter,
Bromma, Sweden); 25 ll CD63-V450 (Cat. No. 561984;
BD). The samples were incubated at room temperature for
15 min and fixed through incubation with 06% CellFIX
(BD) for 10 min. The samples were diluted in Isoflow (Beck-
man Coulter) before being analysed using a Gallios or Navios
flow cytometer (Beckman Coulter). In the FC, the laser set-
ting W2 was used and data were analysed using Kaluza Flow
Cytometry Software (Beckman Coulter). Platelet activation
and degranulation were expressed as percentage of cells posi-
tive for each activation marker or mean fluorescence inten-
sity. LTA and FC analyses of platelet receptors were
performed before genetic analysis in patients from Malm€o.
Transmission electron microscopy
Platelet-rich plasma for TEM was prepared using the follow-
ing protocol. Blood was collected into 2 9 5 ml sodium
citrate 32% tubes and centrifuged at 200 g for 10 min at
20°C. The plasma fraction was transferred to a plastic tube
with 2% glutaraldehyde in 005 mol/l phosphate buffer. The
sample was fixed for 1 h before being centrifuged at 200 g
for 10 min at 20°C. Samples were further processed by the
Core Facility for Integrated Microscopy (CFIM), University
of Copenhagen, Denmark, where they were fixed with 2%
glutaraldehyde in 005 mol/l phosphate buffer for at least
24 h at 4°C. They were then washed three times in 012 mol/
l cacodylate buffer before being post-fixed in 1% OsO4 and
005 mol/l (15%) K3Fe(CN)6 in 012 mol/l cacodylate buffer
for 2 h at room temperature. Samples were washed three
times with water before being incubated with 1% uranyl
acetate for 1 h at 4°C. Following another three washes with
water, they were dehydrated through a graded series of alco-
hol. Samples were infiltrated in a resin and propylene oxide
gradient before being infiltrated with pure resin. They were
then embedded in 100% resin for 24 h at 60°C. Ultra-thin
sections (50 nm) were cut with a Leica EM UC7 microtome
and mounted for examination at 80 kV using a Philips
CM100 transmission electron microscope. Images were
obtained using an Olympus Veleta camera system and iTEM
Table II. €Oresund clinical score.
Score Inheritance
Variants of unknown
significance (VUS)
In silico
analysis
4 AR Homozygous;* Damaging
4 AD Heterozygous;* Damaging
4 XL Hemizygous;* Damaging
3b AR Homozygous;† Damaging
3a AD Heterozygous;† Damaging
3a XL Hemizygous;† Damaging
2b AD Heterozygous;† Benign
2b XL Hemizygous;† Benign
2a AR Heterozygous;† Damaging
1 AR Heterozygous;† Benign
AD, autosomal dominant; AR, autosomal recessive; XL, X-linked.
*Previously reported or supported by screening tests.
†Not previously reported or validated by functional tests.
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FEI software. Patient samples were documented by images
from 50 sections, where each image contained at least one
platelet. Platelet sections from 10 healthy controls were also
assessed in the same manner. The sections were visually
assessed with respect to platelet size as well as the presence
of alpha granules and dense bodies.
Whole-mount electron microscopy with thrombin
stimulation
For evaluation of dense granule secretion in patients with
missense variants in familial haemophagocytic lymphohistio-
cytosis (FHL)-associated genes (UNC13D, STX11, STXBP2),
platelet-rich plasma (prepared as described above) was stim-
ulated with thrombin (01 iu/ml for 3 min) and examined
by whole-mount TEM (White, 2004; Al et al, 2012). The
numbers of dense granules per platelet before and after
thrombin stimulation were counted in patients and in a
control group (20 healthy adults). Fifty images were evalu-
ated from each patient and control. Results were interpreted
as the ratio of dense granule numbers before and after
thrombin stimulation. An aberrant result of >3 standard
deviations (SD) of the control group was considered to be
an indication of decreased dense granule secretion (Fager
et al, 2017).
Immunohistochemistry
To assess platelets and granulocytes, blood smears were either
stained with May-Gr€unwald-Giemsa stain or subjected to
immunofluorescence analysis using a rabbit polyclonal anti-
body against non-muscle myosin IIA (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany).
Multidisciplinary team conference
Each patient’s genetic and functional test results in conjunc-
tion with their clinical phenotype were discussed amongst
the referring clinicians, a genomic biochemist, a clinical bio-
chemist and a clinical geneticist at a multidisciplinary team
(MDT) conference.
Results
Patient characteristics
In total, 156 patients (120 from RH and 36 from Malm€o)
were included in the study. The mean age was
39  15 years (mean  1SD) and 131 (84%) were female.
The majority of patients (71%, 111/156) had a positive
family history of increased bleeding tendency and 30% (47/
156) had thrombocytopenia (defined as a platelet count
below the normal range). The majority of patients were of
European ethnicity (90%). The mean BAT score was
89  6 (1SD) (Fig 1).
Efficacy of WES in diagnostics of IBD
The mean coverage of the exomes of the samples was 84 9 ,
where 9696% of the regions were covered with at least 9 9 .
In total, 353 predominantly missense variants (23 variants
per patient) were detected in 80 of the 87 genes (Table S2),
and at least one variant within the selected 87 genes was
identified in 95% (148/156) of the patients. We found that
5% (8/156 patients) harboured a known pathogenic variant
and were diagnosed with a bleeding disorder as a direct con-
sequence of WES. Of the 345 previously unreported variants,
29% (99) were predicted to be significant by computational
analyses. According to the known Mendelian inheritance pat-
tern of each gene, 17% (59 variants) in 38 patients were pre-
dicted as being significant VUS and assigned an €Oresund
clinical score >2, thus designating them as relevant candi-
dates for further investigations. Variants of unknown signifi-
cance with €Oresund score 1–2 were left as class 3.
Considering patients diagnosed as a consequence of WES, as
well as those harbouring variants selected for further investi-
gations, 29% (46 patients) of our cohort harboured variants
or VUS that could explain or contribute to IBD. As a result
of targeted functional testing and clinical EDS evaluation, 20/
59 (34%) VUS with an €Oresund clinical score >2 were
assigned as novel class 4 or 5 variants. Furthermore, a class 4
or 5 variant was identified in 30% (14/47) of patients with
thrombocytopenia versus 11% (12/109) of patients with a
normal platelet count (P < 001).
Known pathogenic variants
Table III lists all the known pathogenic variants. The patient
characteristics were as follows.
Patient 1. We identified a diagnosis of Glanzmann throm-
basthenia in this patient with mild thrombocytopenia (ho-
mozygosity of ITGB3 (c.31T>C, p.Trp11Arg)) in whom
multiplate analysis demonstrated absent aggregation with all
agonists employed. This patient was also diagnosed with a
mild factor XI deficiency (heterozygosity of F11 (c.1288G>A,
p.Ala430Thr)) with reduced levels of FXI (049 iu/l) (Ref.:
067–127 iu/l). For severe bleeding and major surgery, acti-
vated factor VII would be the choice for haemostatic treat-
ment in this patient.
Patients 46 and 117. An X-linked variant in transcription
factor GATA-1 (c.647G>A, p.Arg216Gln) was found in
Patient 117, a 32-year-old male with macrothrombocytopenia
and severe bleeding tendency. TEM demonstrated clearly
reduced numbers of alpha granules (Fig 2). Red blood cell
morphology was normal. The same variant was found in his
mother, who had a normal platelet count but a severe life-
long bleeding tendency. Patient 46 was diagnosed with X-
linked macrothrombocytopenia without dyserythropoiesis.
He has two daughters and his family will undergo genetic
counselling.
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Patients 64 and 102. Two unrelated patients with normal
size thrombocytopenia harboured a RUNX1 (c.602G>A,
p.Arg201Gln) variant. The older patient (Patient 64) had a
lifelong history of severe thrombocytopenia and bleeding ten-
dency and she developed myelodysplasia when aged 65 years.
She had no children and did not wish to undergo genetic
counselling. However, she had always speculated on the cause
of her illness, which now appeared well resolved. The
younger patient (Patient 102) had a brother and father with
chronic thrombocytopenia who both harboured the same
RUNX1 variant found by polymerase chain reaction analysis
and Sanger sequencing. Neither the younger proband
(Patient 102) nor her RUNX1 variant-positive relatives have
been diagnosed with myelodysplastic syndromes, but they
will undergo genetic counselling and haematological vigi-
lance.
Patient 23. In this patient, with previously unresolved IBD
(BAT score 7) and grey zone levels of VWF [VWF:Ag 039
iu/l (Ref.: 058–169 iu/l) and Ristocetin cofactor (VWF:RCo)
043 iu/l (Ref.: 052–158 iu/l)], a frameshift variant in VWF
(c.2435delC, p.Pro812Argfs*31) was detected, and she was
consequently diagnosed with von Willebrand disease (VWD)
type 1. She now receives appropriate desmopressin treatment
and genetic counselling and carries a von VWD bleeder ID
card.
Patient 60. A patient with inherited blindness (Leber con-
genital amaurosis), thrombocytopenia, giant platelets and
leucocyte inclusion bodies in the peripheral blood smear har-
boured an MYH9 (c.5521G>A, p.Glu1841Lys) variant. This
patient was referred for WES as part of a family investiga-
tion, because three of her first and second degree relatives
had severe bleeding tendency. None of her referred relatives
had thrombocytopenia or MYH9 variants and their bleeding
cause remains unsolved. Patient 60 did not complain of
hearing loss and no proteinuria was detected. The 1841 vari-
ant is only rarely associated with renal problems; however, it
is recommended to test renal function about once a year and
to perform a hearing examination every 5 years in patients
with MYH9-associated thrombocytopenia (Althaus & Greina-
cher, 2010).
Patient 68. An FVIII variant (c.3637delA, p.Ile1213Pfs*5)
was found in Patient 68 who had slight thrombocytopenia
(131 9 109/l) and grey platelets in the peripheral blood
smear. Her brother had severe haemophilia A, however
Patient 68 had never undergone genetic testing prior to
WES. Thus her carrier status was established, facilitating
pregnancy-related genetic counselling. However, no genetic
cause of the thrombocytopenia was found. The FVIII level in
Patient 68 was 056 iu/l (Ref.: 050–15 iu/l).
Novel pathogenic variants (class 5)
As a result of further variant filtering by the €Oresund clinical
score and targeted functional testing, 20 variants were
assigned as novel class 4 or 5 variants (Table IV).
Patient 76. A homozygous frameshift variant in NBEAL2
(c.4928_4929delAT, p.Asp1643Glyfs*34) was concluded to
cause grey platelet syndrome in this 32-year-old female with
a platelet count of 59 9 109/l and grey macrothrombocytes
in the peripheral blood smear. She had previously been mis-
diagnosed with idiopathic thrombocytopenic purpura and
treated with intravenous immunoglobulin and prednisone
during pregnancy without response. FC analysis confirmed
that the CD62P expression on activated platelets was
reduced. Her B12 levels were supranormal (>1200 lmol/l).
Patient 76 will receive platelet transfusions and tranexamic
acid as haemostatic treatment related to severe bleeding and
surgery, genetic counselling and haematological surveillance
for development of splenomegaly and bone marrow fibrosis.
Patient 133. A novel MYH9 (c.3493C>T, p.Arg1165Cys)
variant was identified in Patient 133 with macrothrombocy-
topenia. Leucocyte inclusion bodies were not detected in the
peripheral blood smear but were demonstrated by immuno-
histochemistry, thus revealing the morphology of an MYH9-
associated syndrome. Consequently, this patient will be
Table III. Known pathogenic variants.
Patient Platelet count (9 109/l) Gene Zygosity Variant AA change Type References
68 131 F8 Het c.3637delA p.Ile1213Phefs*5 fs Lin et al (1993)
1 127 F11 Het c.1288G>A p.Ala430Thr m Liu et al (2015)
46 106 GATA1 Hemi c.647G>A p.Arg216Gln m Tubman et al (2007)
117 245 GATA1 Het c.647G>A p.Arg216Gln m Tubman et al (2007)
1 127 ITGB3 Hom c.31T>C p.Trp11Arg m Nurden et al (2015)
60 43 MYH9 Het c.5521G>A p.Glu1841Lys m Saposnik et al (2014)
64 21 RUNX1 Het c.602G>A p.Arg201Gln m Latger-Cannard et al (2016)
102 84 RUNX1 Het c.602G>A p.Arg201Gln m Latger-Cannard et al (2016)
23 292 VWF Het c.2435delC p.Pro812Argfs*31 fs Zhang et al (1992)
Het= heterozygous, Hom=homozygous, Hemi= hemizygous, AA=amino acid, fs=frames-shift variant, m=missense variant.
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examined for proteinuria, cataract and hearing loss, while
severe bleeding and surgery will be treated with desmopressin
and tranexamic acid as prophylactic platelet transfusions are
rarely indicated in MYH9-related thrombocytopenia.
Patient 21. Compound heterozygosity of two variants in
ITGB3 (c.567delA, p.Tyr190Thrfs*17 and c.1525C>T,
p.Gln509*) was discovered in this 71-year-old male with a
lifelong bleeding tendency, slightly reduced platelet count
(143 9 109/l) and a previously unsettled diagnosis, with the
presence of post-platelet transfusion glycoprotein antibodies.
Platelet aggregation was absent by multiplate evaluation. FC
demonstrated <5% GPIIb/IIIa expression and thus confirmed
a suspected diagnosis of Glanzmann thrombasthenia. There-
fore, activated factor VII will be the choice of haemostatic
treatment for this patient for major bleeding and surgery.
Patient 3. Compound heterozygosity of two ITGB3 variants
(c.1192delG, p.Ala398Profs*24 and c.1639T>G, p.Cys547Gly)
and absent platelet aggregation by LTA with all agonists
employed except ristocetin also confirmed a suspected diag-
nosis of Glanzmann thrombasthenia in this patient with sev-
ere bleeding tendency and a normal platelet count.
Patient 33. A patient with a normal APTT (33 s; Ref.: 28–35
s) harboured a variant in F11 (c.599G>A, p.Cys200Tyr). The
bleeding tendency in Patient 33 was characterized by bruising
and oozing following surgical procedures. Specific testing of
the FXI level showed a reduced level (044 iu/l; Ref.: 062–10
iu/l). No other cause of bleeding was found. Consequently,
this patient was concluded to have mild FXI deficiency, thus
indicating treatment with tranexamic acid and fresh frozen
plasma during episodes of severe bleeding, trauma or sur-
gery.
Novel class 4 variants
Patient 47. A WAS variant (c.1208C>T, p.Pro403Leu) was
detected in a young male suffering from a syndrome with
muscle dystonia, mild immune deficiency (reduced IgM and
IgA), infections of the skin and a slightly reduced platelet
count (130 9 109/l). Neither of his parents had thrombocy-
topenia. The peripheral blood smear demonstrated small pla-
telets and his phenotype was identical to an X-linked
thrombocytopenia. The variant was designated as a class 4
because Wiskott-Aldrich Syndrome protein expression was
not analysed. Thus, the cause of immunodeficiency in this
patient was probably resolved by WES.
Patient 106. A variant in the gene encoding the transcrip-
tion factor friend leukaemia integration 1 (FLI1; c.1019G>C,
p.Arg340Pro), located in a highly conserved DNA-binding
S 
(D)
5 μm
3C
E 
(B)
5 μm
(A)
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Fig 2. Transmission Electron Microscopy images. (A) Control: Normal size platelet with average alpha granule content. (B) Image from patient
with a GATA1 variant demonstrating a representative macrothrombocyte and empty alpha granules (E). C and D: Representative platelets from a
patient with an FLI1 variant showing a reduced amount of alpha granules, a giant alpha granule (G) and open platelet structures filled with
glycogen particles [“scrolls” (S)] in the cytoplasm. M, mitochondria.
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domain, was found in this male patient with macrothrombo-
cytopenia (platelet count 131 9 109/l) and severe bleeding
tendency (BAT score 10). TEM demonstrated abnormal
alpha granules with rare scrolls resembling the open platelet
structures filled with glycogen particles previously described
in Medich giant platelet syndrome (Gunning et al, 2013)
(Fig 2C and D). Family linkage studies showed that the
mother of Patient 106 and her two sisters with thrombocy-
topenia harboured the same FLI1 variant. The platelet counts
of one of his mother‘s sisters and of his half-brother were
normal and they both carried an FLI1 wildtype.
Patients 16, 92 and 151. A recurrent variant in NBEA
(c.8350G>T, p.Val2784Phe) was identified in two unrelated
patients with normal platelet counts. They both exhibited a
reduced number of dense granules on TEM examination.
Decreased ATP release by LTA was demonstrated in one
patient (Patient 92) and the other patient (Patient 16) had
a reduced response to arachidonic acid and collagen by
multiplate analysis. Hence, the variant was concluded to be
probably pathogenic. Given that the brother of Patient 16
required bone marrow transplantation, a search for an
unrelated donor was initiated and identified due to the sus-
picion of an inherited platelet disorder. Another NBEA vari-
ant (c.1185A>C, p.Glu395Asp) was identified in Patient
151, who had a family history, lifelong bleeding tendency
(BAT score 11) and a recent diagnosis of antiphospholipid
antibody syndrome (APAS) with multiple arterial throm-
boses. She therefore received warfarin treatment and experi-
enced prolonged and transfusion-demanding bleeding
following surgery, even though warfarin was appropriately
paused preoperatively and she was not treated with antipla-
telet agents. FC demonstrated impaired expression of CD63
and TEM showed a reduced amount of dense granules. A
probable diagnosis of delta storage pool deficiency was con-
cluded. Due to APAS and risk of thrombosis, Patient 151
cannot be treated with tranexamic acid or desmopressin for
future surgeries, and thus enhanced surgical haemostatic
procedures should be ensured.
Patients 49 and 13. A previously unreported heterozygous
GP1BA variant (c.58T>G, p.Cys20Gly) was identified in a
patient (Patient 49) without significant bleeding tendency
but with chronic thrombocytopenia (68 9 109/l) and 50%
giant platelets in the peripheral blood smear,. FC showed
reduced expression of GP1BA and normal expression of pla-
telet activation markers (CD62P, PAC-1, CD63). A probable
diagnosis of monoallelic Bernard-Soulier syndrome (BSS)
was therefore concluded. Three more patients with low plate-
let counts (44–94 9 109/l) and giant platelets in the periph-
eral blood smear harboured a shared rare heterozygous
variant in GP1BA (c.247C>T, p.Leu83Phe). In one of these
patients (49), FC showing reduced levels of GP1BA was again
diagnostic of monoallelic BSS. The two other patients are
pending further functional testing.T
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Patient 136. A RUNX1 (c.308C>T, p.Pro103Leu) variant
was detected in this 38-year-old woman with thrombocy-
topenia. FC analysis of her platelet function showed impaired
CD63 expression, indicating dense granule deficiency. More-
over, her son, father, grandfather and cousin suffered from
bleeding symptoms and thrombocytopenia, and her sister
was diagnosed with myelodysplastic syndrome. An identical
RUNX1 variant was found in her six-year-old son, who had
a platelet count of 79 9 109/l. The family will receive haema-
tological surveillance and genetic counselling.
Patient 20. A thromboxane synthase (PTGS1) variant
(c.337C>T, p.Arg113Cys) was identified with another PTGS1
variant (c.1003G>A, p.Val481Ile) with a relatively high fre-
quency in the background population (077%) in Patient 20,
who had a normal platelet count and severe bleeding ten-
dency. Her levels of thromboxane B2 (TBXB2) in plasma
were reduced compared to controls and a probable diagnosis
of prostaglandin synthase-1 deficiency was concluded. Patient
20 has been advised to avoid antiplatelet agents and non-
steroidal anti-inflammatory drugs and receives tranexamic
acid treatment for minor bleeding. A family investigation of
her two sons is ongoing, as they both present with bleeding
problems.
Patients 127, 123 and 54. Three patients harboured collagen
variants [Patient 127: COL1A1 (c.4018G>A, p.Gly1340Ser),
Patient 123: COL1A1 (c.436C>A, p.Pro146Thr) and Patient
54: COL5A1 (c.193C>T, p.Arg65Trp)] that were classified as
probable pathogenic class 4 variants because the patients ful-
filled the clinical criteria of classical type of EDS based on a
clinical evaluation performed by a rheumatologist expert in
EDS. Patient 127 also harboured a damaging variant in
COL3A1 but Patient 127 did not fulfill the clinical criteria of
vascular of type EDS, thus the COL3A1 variant was left as a
class 3. The treatment of EDS requires an MDT and Patients
127, 123 and 54 will be referred to rheumatologist care and
physical therapy. Haemostatic treatment includes tranexamic
acid, desmopressin and meticulous stitching following inva-
sive procedures.
Patient 62. Studies in rodents have indicated an increased
bleeding tendency in heterozygous carriers of variants in genes
associated with FHL due to the impaired release of procoagu-
lant mediators by platelet degranulation (Ren et al, 2010).
These findings prompted us to conduct specific functional
testing in 12 patients with heterozygous VUS with an €Oresund
clinical score of 2a in the FHL-associated genes UNC13D,
STX11 and STXBP2. Impaired secretion from platelet dense
granules by at least one of the assays (whole-mount TEM, LTA
and FC) was confirmed in eight of the patients as compared to
healthy controls. In patient 62, harbouring UNC13D
(c.466C>T, p.Arg156Trp), this variant was strongly associated
with impaired dense granule secretion following thrombin
stimulation. Consequently, Patient 62 was assigned a probable
diagnosis of impaired platelet dense granule secretion linked to
a heterozygous UNC13D variant (Fager et al, 2017).
Discussion
Whole exome sequencing is rapidly being implemented as a
diagnostic tool for a wide spectrum of haematological diseases
(Camps et al, 2016; Hansen et al, 2016; Leinoe et al, 2016;
Zhang et al, 2016). Prompted by the diagnostic conundrum
for the majority of IBD - suspected patients, we adopted WES
into the diagnostic strategy at our institutions. This approach
was made possible due to a pre - established in-house genomic
centre and an existing close collaboration between the two
coagulation units localized in the €Oresund Region. To date, in
the diagnostic work-up of rare IBD, NGS-based gene panels
have been implemented by two large research collaborations:
the ThromboGenomics platform (Simeoni et al, 2016) and the
GAPP study group (Johnson et al, 2016). We implemented
WES in our clinics, allowing consecutive expansion of the
number of genes analysed. We included both platelet- and
non-platelet-related genes in the IBD gene panel and report a
higher number of class 4 and 5 variants in patients with
thrombocytopenia compared to those with normal platelet
counts. The genetic diagnosis of rare IBD with normal platelet
counts is hampered by a knowledge gap, while it is estimated
that the genetic causes of thrombocytopenia have been identi-
fied in approximately 50% of patients (Johnson et al, 2016).
One of the greater challenges we encountered in the process
was the classification of VUS in the many relatively new genes
and their subsequent translation into clinical practice. Hence,
we developed the €Oresund clinical score as a simple pragmatic
approach, incorporating in silico predictions with inheritance
patterns to assess the possible clinical relevance of the identi-
fied variants and to select for downstream specific functional
testing. The €Oresund clinical score led to 59 possible clinically
relevant VUS in 38 patients, of which 20 (34%) were assigned
as novel class 4 or 5 variants. To address the constraint that in
silico analyses are never 100% accurate (Thusberg et al, 2011),
we combined four in silico methods for variant filtering to
direct the specific functional studies. Nevertheless, the selec-
tion of variants for downstream functional testing using the
€Oresund clinical score may have caused false negative results.
The clinical usability of the €Oresund clinical score needs to be
evaluated in an independent patient cohort, where functional
testing of all identified VUS is performed.
Eight patients (5%) were diagnosed as a direct conse-
quence of WES, and 20 previously unreported class 4 or 5
variants were identified in 12% (18/156) of patients. An IBD
diagnosis has a major clinical impact. The genetic investiga-
tions detailed here extricated our patients from a diagnostic
conundrum. The remaining 83% (130 patients) rendered
without a proper diagnosis may harbour pathogenic variants
in unknown genes or regulatory regions or their IBD might
result from a multigenic inheritance mode. Exome sequenc-
ing carries the fundamental limitation of not being able to
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assess the impact of regulatory and non-coding regions. The
genetic background of IBD is likely to be heterogeneous with
contributions from multiple genetic alterations, which may
also interact with acquired factors such as comorbidity and
medications (Watson et al, 2013). Combined heterozygous
variants, particularly in genes involved in signalling pathways,
platelet granule trafficking or granule biogenesis, may result
in a severe bleeding phenotype. Thus, extended functional
testing of compound heterozygous variants in the same bio-
logical pathways warrants further investigations.
Fourteen patients (9%) had a VUS in collagen genes
(COL5A1, COL5A2, COL3A1 and COL1A1) predicted to be
damaging by in silico analyses. However, only three collagen
variants were classified as probable pathogenic class 4 vari-
ants in patients fulfilling the clinical criteria of autosomal
dominant inherited EDS. Collagen mediates platelet adhesion
and activation following injury to the vascular wall and is
essential for the maintenance of haemostasis (Manon-Jensen
et al, 2016). It is currently unclear whether collagen missense
variants are causal of the bleeding tendency in patients not
fulfilling the clinical EDS criteria. Of particular interest, only
one of our patients had a (benign) variant in the gene
(P4HB) encoding PDI, indicating that PDI variants were not
a common cause of bleeding disorders in our patient cohort.
We anticipate that an additional number of our patients will
be diagnosed by WES, especially those patients with a normal
platelet count, given the considerable efforts that are cur-
rently being directed towards the discovery of new causal
variants in IBD patients (Bariana et al, 2017; Johnson et al,
2016; Simeoni et al, 2016).
It is highly probable that numerous bleeding-associated
genes will be discovered in the coming years. These efforts will
inevitably lead to an optimized annotation of novel variants in
the increasing number of genes found to predispose to bleeding,
and will therefore allow early genetic analysis to be more effi-
ciently translated into clinical practice. The advantage of WES,
in comparison to custom capture gene panels, is that it enables
expansion by analysing newly assigned IBD-predisposing genes.
The disadvantages of WES analysis in a diagnostic clinical set-
ting are that it requires a genomic sequencing laboratory in
combination with data scientist with NGS-data analysis exper-
tise. Once an atomized pipeline has been established, the man-
ual labour of a WES analysis is in line with a single gene
analysis. For example, in our setting, a WES analysis including
diagnostic report can be ready within three weeks from blood
sample submission. The expenses of a WES analysis are cost
effective provided that the diagnosis was not established by the
primary genetic analysis (Stark et al, 2017). Implementing WES
at an early phase of the work-up of IBD may eliminate the need
for complex and expensive laboratory analyses. However, trans-
lating the comprehensive results of genetic analysis into haema-
tological practice requires an efficient multidisciplinary pipeline
represented by a number of specialized centres, e.g. genomic
medicine, integrated microscopy and FC, coagulation labora-
tory, clinical genetics and rheumatology. The multidisciplinary
efforts are particularly relevant when the examined genes
include syndromes with bleeding phenotypes not associated
with a platelet disorder.
In conclusion, we found that WES of predefined genes is
a powerful tool for elucidating potential pathogenic variants
in patients with IBD and a feasible method to direct specific
functional testing by FC and TEM. Looking forward, we
intend to proceed with this approach, relying on up-front
WES to guide downstream personalised laboratory diagnostic
procedures and to expand the exciting functional tests.
Patients with thrombocytopenia are often misdiagnosed with
idiopathic thrombocytopenic purpura, which may prompt
ineffective and potentially harmful treatment with immuno-
suppressive therapy, intravenous immunoglobulin and
splenectomy. Hence, a diagnosis of IBD can have important
clinical implications beyond specific haemostatic treatment
and genetic counselling. Our study supports the view that
continuously aiming to improve the diagnostic work-up of
IBD is of great benefit.
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